498 related articles for article (PubMed ID: 32613971)
21. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L
Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189
[TBL] [Abstract][Full Text] [Related]
23. Potently neutralizing and protective human antibodies against SARS-CoV-2.
Zost SJ; Gilchuk P; Case JB; Binshtein E; Chen RE; Nkolola JP; Schäfer A; Reidy JX; Trivette A; Nargi RS; Sutton RE; Suryadevara N; Martinez DR; Williamson LE; Chen EC; Jones T; Day S; Myers L; Hassan AO; Kafai NM; Winkler ES; Fox JM; Shrihari S; Mueller BK; Meiler J; Chandrashekar A; Mercado NB; Steinhardt JJ; Ren K; Loo YM; Kallewaard NL; McCune BT; Keeler SP; Holtzman MJ; Barouch DH; Gralinski LE; Baric RS; Thackray LB; Diamond MS; Carnahan RH; Crowe JE
Nature; 2020 Aug; 584(7821):443-449. PubMed ID: 32668443
[TBL] [Abstract][Full Text] [Related]
24. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK
Front Immunol; 2020; 11():1880. PubMed ID: 32973779
[TBL] [Abstract][Full Text] [Related]
25. Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Zhang C; Zhou C; Shi L; Liu G
Hum Vaccin Immunother; 2020 Oct; 16(10):2366-2369. PubMed ID: 32961082
[TBL] [Abstract][Full Text] [Related]
26. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.
Shi R; Shan C; Duan X; Chen Z; Liu P; Song J; Song T; Bi X; Han C; Wu L; Gao G; Hu X; Zhang Y; Tong Z; Huang W; Liu WJ; Wu G; Zhang B; Wang L; Qi J; Feng H; Wang FS; Wang Q; Gao GF; Yuan Z; Yan J
Nature; 2020 Aug; 584(7819):120-124. PubMed ID: 32454512
[TBL] [Abstract][Full Text] [Related]
27. Immunoglobulin fragment F(ab')
Pan X; Zhou P; Fan T; Wu Y; Zhang J; Shi X; Shang W; Fang L; Jiang X; Shi J; Sun Y; Zhao S; Gong R; Chen Z; Xiao G
Antiviral Res; 2020 Oct; 182():104868. PubMed ID: 32659292
[TBL] [Abstract][Full Text] [Related]
28. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
[TBL] [Abstract][Full Text] [Related]
29. Designing Multi-Epitope Vaccines to Combat Emerging Coronavirus Disease 2019 (COVID-19) by Employing Immuno-Informatics Approach.
Naz A; Shahid F; Butt TT; Awan FM; Ali A; Malik A
Front Immunol; 2020; 11():1663. PubMed ID: 32754160
[TBL] [Abstract][Full Text] [Related]
30. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
Huo J; Zhao Y; Ren J; Zhou D; Duyvesteyn HME; Ginn HM; Carrique L; Malinauskas T; Ruza RR; Shah PNM; Tan TK; Rijal P; Coombes N; Bewley KR; Tree JA; Radecke J; Paterson NG; Supasa P; Mongkolsapaya J; Screaton GR; Carroll M; Townsend A; Fry EE; Owens RJ; Stuart DI
Cell Host Microbe; 2020 Sep; 28(3):445-454.e6. PubMed ID: 32585135
[TBL] [Abstract][Full Text] [Related]
31. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2.
Yu F; Xiang R; Deng X; Wang L; Yu Z; Tian S; Liang R; Li Y; Ying T; Jiang S
Signal Transduct Target Ther; 2020 Sep; 5(1):212. PubMed ID: 32963228
[TBL] [Abstract][Full Text] [Related]
32. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana.
Rattanapisit K; Shanmugaraj B; Manopwisedjaroen S; Purwono PB; Siriwattananon K; Khorattanakulchai N; Hanittinan O; Boonyayothin W; Thitithanyanont A; Smith DR; Phoolcharoen W
Sci Rep; 2020 Oct; 10(1):17698. PubMed ID: 33077899
[TBL] [Abstract][Full Text] [Related]
33. Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development.
Calina D; Sarkar C; Arsene AL; Salehi B; Docea AO; Mondal M; Islam MT; Zali A; Sharifi-Rad J
Immunol Res; 2020 Dec; 68(6):315-324. PubMed ID: 33006053
[TBL] [Abstract][Full Text] [Related]
34. What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist.
Palatnik-de-Sousa CB
Front Immunol; 2020; 11():2173. PubMed ID: 32983183
[No Abstract] [Full Text] [Related]
35. A systematic review of SARS-CoV-2 vaccine candidates.
Dong Y; Dai T; Wei Y; Zhang L; Zheng M; Zhou F
Signal Transduct Target Ther; 2020 Oct; 5(1):237. PubMed ID: 33051445
[TBL] [Abstract][Full Text] [Related]
36. The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome Coronavirus.
Jiang S; Shi ZL
Virol Sin; 2020 Jun; 35(3):263-265. PubMed ID: 32060789
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
38. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.
Rogers TF; Zhao F; Huang D; Beutler N; Burns A; He WT; Limbo O; Smith C; Song G; Woehl J; Yang L; Abbott RK; Callaghan S; Garcia E; Hurtado J; Parren M; Peng L; Ramirez S; Ricketts J; Ricciardi MJ; Rawlings SA; Wu NC; Yuan M; Smith DM; Nemazee D; Teijaro JR; Voss JE; Wilson IA; Andrabi R; Briney B; Landais E; Sok D; Jardine JG; Burton DR
Science; 2020 Aug; 369(6506):956-963. PubMed ID: 32540903
[TBL] [Abstract][Full Text] [Related]
39. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2.
Lin L; Ting S; Yufei H; Wendong L; Yubo F; Jing Z
Virus Res; 2020 Oct; 288():198082. PubMed ID: 32621841
[TBL] [Abstract][Full Text] [Related]
40. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.
Hanke L; Vidakovics Perez L; Sheward DJ; Das H; Schulte T; Moliner-Morro A; Corcoran M; Achour A; Karlsson Hedestam GB; Hällberg BM; Murrell B; McInerney GM
Nat Commun; 2020 Sep; 11(1):4420. PubMed ID: 32887876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
